期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺腺癌临床病理研究新进展 被引量：27

下载PDF
导出
摘要 肺腺癌作为肺癌常见组织学类型,约占肺癌的50%。不同组织亚型的肺腺癌在临床、影像学、病理学和遗传学上有很大差异。近年来,对该肿瘤的基础和临床探讨取得了明显进步,国际肺癌研究学会(IASLC)、美国胸科学会(ATS)和欧洲呼吸学会(ERS)于2011年2月公布肺腺癌的国际多学科分类。该文就近年来肺腺癌临床病理学相关进展进行综述。
作者 杨清海 陈惠玲 郑智勇
机构地区 福建医科大学福总临床医学院(南京军区福州总医院)病理科 福州迈新生物技术开发有限公司技术中心
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2014年第1期53-55,60,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 肺肿瘤 腺癌 病理 临床 分类 文献综述
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Yoshizawa A, Motoi N, Riely G J, et al. hnpact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognos- tic subgroups and implications for further revision of staging based on analysis of 514 stage I cases [ J ]. Mod Pathol, 2011,24 ( 5 ) : 653 - 64.
  • 2Travis W D, Brarnbilla E, Van Schil P, et ul. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/EFIS lung adeno- carcinoma elassifieation [ J ]. Eur Respir J, 2011,3g (2) :239 - 43.
  • 3朱雄增,张杰.肺腺癌IASLC/ATS/ERS国际多学科分类解读[J].临床与实验病理学杂志,2012,28(3):241-243. 被引量：33
  • 4周晓军,刘标.解读2011年IASLC/ATS/ERS肺腺癌国际多学科分类[J].临床与实验病理学杂志,2011,27(8):801-805. 被引量：35
  • 5Warth A, Muley T, Meister M, et al. The novel histologic Interna- tional Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival [ J ]. J Clin Oncol, 2012,30( 13 ) :1438 -46.
  • 6Borczuk A C, Qian F, Kazeros A, et al. Invasive size is an inde- pendent predictor of survival in pulmonary adenocarcinoma[J]. Am J Surg Pathol, 2009,33(3) :462.
  • 7Maeshima A M, Tochigi N, Yoshida A, et al. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator[ J ]. J Thoracic Oncol, 2010,5 (3) :333 - 9.
  • 8Russell P A, Wainer Z, Wright G M, et al. Does lung adcnocarci- noma subtype predict patient survival? A clinicopathologic study based on the new International association for the study of lung cancer/American thoracic society/European respiratory society in- ternational muhidisciplinary lung adenocarcinoma classification [ J 1. J Thoracic Oncol, 2011,6 (9) : 1496 - 504.
  • 9Warth A, Stenzinger A, yon Briinneck A C, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classifi- cation for pulmonary adenocarcinomas[ J1. Eur Respir J, 2012,40 (5) :1221 -7.
  • 10刘标,周晓军.非小细胞肺癌个体化治疗的靶向分子检测[J].临床与实验病理学杂志,2012,28(8):831-837. 被引量：28

二级参考文献21

  • 1Pirker R, Herth F J F, Kerr K, et al. Consensus for EGFR muta- tion testing in non-small cell lung cancer: results from a european workshop[ J]. J Thorae Oncol, 2010,5 (10) : 1706 - 13.
  • 2Ellis P M, Blais N, Soulieres D, et al. A systematic review and canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer [ J ]. J Thorac Oncol, 2011,6(8) :1379 -91.
  • 3Saho-Tellez M, Tsao M S, Shih J Y, et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor muta- tions in east asian patients with non-small cell lung cancer : a combined clinical-molecular pathological approach [ J ]. J Thorac Oncol,2011,6 ( 10 ) : 1663 - 9.
  • 4Pirker R, Pereira J R, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3 FLEX study[J]. Lancet Oncol, 2012,13 ( 1 ) :33 -42.
  • 5Varella-Garcia M, Diebold J, Eberhard D A, et al. EGFR fluo- rescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer[ J]. J Clin Pathol, 2009,62( 11 ) :970 -7.
  • 6Soda M, Choi Y L, Enomoto M, et al. Identification of the trans- forming EMIA-ALK fusion gene in non-small-cell lung cancer[ J ]. Nature, 2007 (7153) ,448:561 - 6.
  • 7Zhang X C, Zhang S, Yang X N, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression[ J]. Mol Cancer, 2010,9 : 188.
  • 8Yang J, Zhang X, Su J, et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer[ J]. J Clin Oncol,2011,29 (Suppl) : 10517 [ Abstr ].
  • 9Mino-Kenudson M, Chirieac L R, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rear- ranged lung adenocarcinomas by standard immunohistochemistry [J]. ClinCancerRes, 2010,16(5) :1561-71.
  • 10Yi E S, Boland J M, Maleszewski J J, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carci- noma: IHC score algorithm for FISH [ J ]. J Thorac Oncol, 2011,6 (3) :459 -65.

共引文献86

同被引文献215

  • 1Paul E.VAN SCHIL Michèle DE WAELE Jeroen M.HENDRIKS Patrick R.LAUWERS.Is there a role for surgery in stage ⅢA-N2 non-small cell lung cancer?[J].中国肺癌杂志,2008,11(5):615-621. 被引量：14
  • 2段惠洁,顾国民,王秀丽,刘春玲.培美曲塞联合奈达铂一线方案治疗晚期肺腺癌的临床研究[J].肿瘤防治研究,2014,41(1):61-64. 被引量：19
  • 3许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量：1366
  • 4李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医,2005,23(7):5-6. 被引量：32
  • 5Rossi G, Cavazza A, Righi L, et al. Napsin-A, TTF-1, EGFR, and ALK status determination in lung primary and metastatic mu- cin-Producing adenocarcinomas[ J]. Int J Surg Pathol, 2014 : 22 (5) :401 -7.
  • 6Montezuma D, Azevedo R, Lopes P, et al. A panel of four inmm- nohistoehemieal markers (CKT, CK20, TfF-1 , and p63 ) allows accurate diagnosis of primary and metastatic lung carcinoma on bi- opsyspecimens [ J 1. Virchows Arch, 2013,463 ( 6 ) :749 - 54.
  • 7Lee J S, Kim H R, Lee C Y, et al. EGFR and TTF-1 gene ampli- fieation in surgically resected lung adenoearcinomas: elinieopatho- logic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases [ J]. Ann Surg Oncol, 2013,20 ( 9 ) : 3015 -22.
  • 8Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours[J]. Eur J Cancer, 1996,32A(3) :512 - 7.
  • 9Nicholson A G, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR statusof non-small cell lung carcinoma in biopsy and cy- tologic material, using a panel of mucin staining, TTF-1, cytoker- atin 5/6, and p63, and EGFR mutation analysis[J ]. J Tborac Oncol, 2010,5(4) :436 -41.
  • 10Thunnissen E, Boers E, Heideman D A, et al. Correlation of im- munohistochemical staining p63 and TI'F-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma [ J ]. Virchows Arch, 2012,461 ( 6 ) : 629 - 38.

引证文献27

二级引证文献106

临床与实验病理学杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部